07:22 AM EST, 12/13/2024 (MT Newswires) -- Blackstone (BX) and Bain Capital are among the final bidders for Mitsubishi Tanabe Pharma, a subsidiary of Japan's Mitsubishi Chemical Group, in a deal potentially valued at between $3 billion and $3.5 billion, Reuters reported on Friday, citing three sources.

Mitsubishi Chemical has enlisted Goldman Sachs ( GS ) to manage the sale, with binding bids due by Dec. 24, according to the report.

Local private equity firm Japan Industrial Partners is also in the running, according to Reuters.

Blackstone, Bain Capital, Goldman Sachs ( GS ), and Mitsubishi Chemical did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)